Supplementary Table S4 from A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas
Year: 2024
Type: supplementary-materials
Abstract: Supplementary Table S4. ADAs among patients with PFS >6, >12, and >24 months.
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4404423606